The use of thiazolidinediones, drugs for type 2 diabetes that may also be useful for other chronic inflammatory disorders, is limited by fluid retention. Research in mice identifies a mechanism for this side effect and introduces a potential remedy (pages 861–866).
References
Zhang, H. et al. Proc. Natl. Acad. Sci. USA 102, 9406–9411 (2005).
Guan, Y. et al. Nat. Med. 11, 875–879 (2005).
Rubins, H.B. et al. N. Engl. J. Med. 341, 410–418 (1999).
Yki-Jarvinen, H. N. Engl. J. Med. 351, 1106–1118 (2004).
Sidhu, J.S., Kaposzta, Z., Markus, H.S. & Kaski, J.C. Arterioscl. Thromb. Vasc. Biol. 24, 930–934 (2004).
Nesto, R. et al. Circulation 108, 2941–2948 (2003).
Gamble, J.L., Ross, G.S. & Tisdall, F.F. J. Biol. Chem. 57, 633–695 (1923).
Atchley, D.W., Loeb, R.F., Richards, D.W., Benedict, Jr., E.M. & Driscoll, M.E. J. Clin. Invest. 12, 297–326 (1933).
Miller, J.H. & Bogdonoff, M.D. J. Appl. Physiol. 6, 509–512 (1954).
Devasthale, P.V. et al. J. Med. Chem. 48, 2248–2250 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Semenkovich, C. TZDs and diabetes: testing the waters. Nat Med 11, 822–824 (2005). https://doi.org/10.1038/nm0805-822
Issue Date:
DOI: https://doi.org/10.1038/nm0805-822
- Springer Nature America, Inc.
This article is cited by
-
Preserved Response to Diuretics in Rosiglitazone-Treated Subjects With Insulin Resistance: A Randomized Double-Blind Placebo-Controlled Crossover Study
Clinical Pharmacology & Therapeutics (2011)